Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
Nicola Squillace,1 Giorgio Bozzi,2 Elisa Colella,1 Andrea Gori,2 Alessandra Bandera1 1Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 2Infectious Disease Unit, Department of Internal Medicine, Fondazione IRCC...
Main Authors: | Squillace N, Bozzi G, Colella E, Gori A, Bandera A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-safety-and-ef-peer-reviewed-article-DDDT |
Similar Items
-
A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation
by: Challamalla Pavani, et al.
Published: (2022-01-01) -
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
by: Bruce Rashbaum, et al.
Published: (2019-01-01) -
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
by: Marianne Harris, et al.
Published: (2017-11-01) -
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
by: Crutchley RD, et al.
Published: (2016-03-01) -
Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure
by: Alberton F, et al.
Published: (2024-04-01)